Swiss cannabis study halted for purity concerns

by Duncan Fisher

September 15, 2022 - 2 min read

The Swiss city of Basel has put a hold on the launch of ‘Weed Care’, Europe’s first recreational cannabis trial, due to concerns over product ‘quality standards’. Source cannabis analysis has found0.1-0.2 parts per million of fluopyram, a pesticide not certified for organic cultivation. ‘Organic’ was part of the legal stipulation for the study’s approval. This production protocol subjects the purity of the harvested cannabis to environmental variables, like soil contaminants, and pesticide residue. Lino Cereghetti, chief operating officer of Pure Production AG, supplier of the source cannabis, suggests that there may be reasonable warrant for review of the experimental statute governing this study. The quantity of fluopyram found in the assay are well within the acceptable range for ordinary produce. Part of the function of pilot studies like this, he observes, besides establishing real-world benefits data, is to judge to what degree studies in general may be over-regulated. 

The problem of purity, and its sibling problem, consistency, are unavoidable in agriculture-based production. Industrial assembly of cannabinoids by synthetic means bypasses this. Using non-cannabis source material obviates any need for testing for THC content in pharmaceutical or practitioner-grade products as well. If THC is required in a product, as in the case of the Weed Care study, this too can be managed without a cannabis precursor, and the amounts can be assured with precision. These techniques are fully scalable, moreover, and do not rely on harvesters’ success with yearly crop yields. 


DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 


Beyond glaucoma: Cannabinoids in ophthalmology

Beyond glaucoma: Cannabinoids in ophthalmology

Cannabinoids appear to have therapeutic potential in glaucoma. Beyond this, there may be further promise in ophthalmology.
Read More

December 05, 2022 1 min read

The endocannabinoid system and bone disease

The endocannabinoid system and bone disease

Stimulation of the endocannabinoid system modulates bone formation and bone resorption. There may be a role one day for targeted drugs in osteoporosis and some forms of bone cancer. 
Read More

December 02, 2022 1 min read

Sex differences, endocannabinoids, and pain

Sex differences, endocannabinoids, and pain

Sex differences in pain perception and analgesia is a burgeoning research field overall. What about cannabinoid analgesia specifically? 
Read More

December 01, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00
Shipping
Total

Shipping Address

Shipping Methods